Integrative Oncology: Hope or hype in cancer Care?
A growing movement in cancer treatment, known as integrative oncology, aims to treat patients holistically-but faces skepticism from some medical professionals regarding the scientific validity of its methods.
The core tenet of integrative oncology is a shift from disease-centered to patient-centered care. “Our ideology is to move from medicine centered on the disease to medicine centered on the individual,” explained Alain Toledano, a leading advocate for the approach, in an interview with AFP. Toledano co-founded the Rafaël Institute in 2018, which he claims is the “first European integrative medicine center,” adn has as spearheaded the creation of an “integrative health” chair and the French Society of Integrative Oncology.
France’s national cancer plan, unveiled in 2023, recognizes certain complementary therapies – including pain management, dietary support, and physical activity – as “essential” and reimbursable by health insurance due to demonstrated effectiveness. Though, integrative approaches frequently enough extend to therapies like naturopathy, homeopathy, sensory immersion, and auriculotherapy, offered at centers like the Rafaël Institute.
This is where the core disagreement lies.According to Professor Norbert Ifrah, president of INCa, these latter practices “have not scientifically proven their effectiveness in improving the chances of recovery or quality of life of patients” and are more accurately categorized as relating to “well-being.”
The question of effectiveness is fiercely contested. Toledano asserts that his institute rigorously evaluates each treatment through patient-reported outcomes, gathering “quantitative and qualitative evaluations.” However, a research fellow at the Montpellier Cancer Institute countered that these evaluations are “not studies but simple collection of opinions.” The boundary, he argued, “should be defined by proof, not satisfaction,” notably when treatments are offered free of charge, as they are at the Rafaël Institute, which relies on patronage and donations.
Concerns extend to the financial backing of the movement. A senior official pointed out that the French Society of Integrative Oncology (SFOI) receives support from “well-being” laboratories, including Boiron, a major homeopathy manufacturer. At a recent SFOI congress, a session was dedicated to the “top 10” homeopathic treatments in oncology, despite homeopathy having lost its reimbursement status in France in 2021 due to a lack of proven efficacy, as steadfast by the High Health Authority.
While acknowledging the potential benefits of complementary therapies, experts caution against unsubstantiated claims. “Fighting the speeches presenting them as miracles is critically important,” noted a director of research and development at Unicancer, “though it is indeed not a question of banning plants, essential oils or homeopathy, the effectiveness of which cannot be scientifically proven with the same level of proof as a drug.”
The National Council of the Order of Physicians (Cnom) recognizes a “gray zone” where the term “integrative” is used to legitimize unproven or unregulated practices. Naturopathy, for example, lacks scientific validation and recognized training standards. One physician expressed concern that promoting unproven treatments,”under the pretext that it does no harm,” could open the door to “sectarian aberrations.”
However, the approach isn’t universally dismissed. According to the secretary general of the French Cancer Society, integrative oncology can be “relevant” when approached “scientifically” and “without false promises.” Emerging data suggest potential benefits for practices like acupuncture, yoga, and relaxation techniques, though the evidence remains moderate.
Ultimately,some argue that resources should be directed towards strengthening existing supportive care within established cancer treatment centers,rather than funding unproven approaches. As one oncologist stated, the focus should be on bolstering what works, not diverting resources to what hasn’t been demonstrated to improve patient outcomes.
